China High Quality Tianeptine Sodium Salt Factories – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We know that we only thrive if we can easily guarantee our combined cost competiveness and high-quality advantageous at the same time for Ethylene Carbonate, Iodonitrotetrazolium Chloride, Ethylene Carbonate, As an experienced group we also accept customized orders. The main goal of our company is to build up a satisfying memory for all customers, and establish a long-term win-win business relationship.
China High Quality Tianeptine Sodium Salt Factories – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality Tianeptine Sodium Salt Factories –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

"Quality 1st, Honesty as base, Sincere company and mutual profit" is our idea, in an effort to create consistently and pursue the excellence for China High Quality Tianeptine Sodium Salt Factories – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Bhutan, Barcelona, Yemen, By adhering to the principle of "human oriented, winning by quality", our company sincerely welcomes merchants from at home and abroad to visit us, talk business with us and jointly create a brilliant future.
  • Hope that the company could stick to the enterprise spirit of "Quality, Efficiency, Innovation and Integrity", it will be better and better in the future.
    5 Stars By Daisy from Lithuania - 2017.10.27 12:12
    It is not easy to find such a professional and responsible provider in today's time. Hope that we can maintain long-term cooperation.
    5 Stars By Jean Ascher from Costa Rica - 2017.10.25 15:53
    Write your message here and send it to us

    Related Products